TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03425448
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin hemodialysis catheter lock solution
Study: NCT01393600
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution containing no active substance
Study: NCT00850096
Drug: Nasulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal insulin (glargine) administered as a 1x daily injection in the morning and two (50 IU) or four (100 IU) sprays of Nasulin (intranasal insulin spray 1%) administered three times daily just prior to meals for 6 weeks.
Study: NCT02789475
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin administration
Study: NCT02633930
Drug: clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin-containing quadruple therapy group 500 mg 1 tablet BID plus amoxicillin 500 mg 2 capsules BID, lansoprazole 30mg 1tablet BID, and colloidal bismuth tartrate capsule55 mg 4 capsules BID.
Study: NCT00433550
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: given orally
Study: NCT02653638
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. Transcranial Doppler~2. Blood Pressure~3. Heart Rate~4. Oxygen Saturation
Study: NCT01373450
Drug: Oxyntomodulin
Normalized name: Oxyntomodulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 pmol/kg/min as an intravenous (IV) infusion in the morning of the day of graded glucose infusion (GGI) (Day 1)
Study: NCT02084576
Drug: Nepafenac
Normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One drop in the study eye 3 times daily for 30 days
Study: NCT02084576
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One drop in the study eye 4 times daily for 30 days
Study: NCT04616105
Drug: REGN6490
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of REGN6490
Study: NCT04616105
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching single dose of REGN6490
Study: NCT00361166
Drug: ACP-103
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00619164
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet taken orally, once a day.
Study: NCT02671825
Drug: PUR0200
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUR0200 dry powder inhalation
Study: NCT02671825
Drug: Reference Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry Powder Inhalation Reference Product
Study: NCT00984061
Drug: clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250 mg clarithromycin tablet taken on an outpatient basis twice daily at 8am and 8pm for 14 doses (starting with 8pm dose on Day 22 and concluding with 8am dose on Day 29)
Study: NCT03221140
Drug: Outpatient parenteral antimicrobial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of intravenous antimicrobials on an outpatient basis
Study: NCT03607188
Drug: Alkotinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alkotinib 200mg QD、 Alkotinib 300mg QD、 Alkotinib 400mg QD、 Alkotinib 500mg QD、 Alkotinib 600mg QD
Study: NCT00460265
Drug: ARM 2
Normalized name: Surgitube Arm 2 5/8x50"
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive Cisplatin plus 5FU
Study: NCT02289846
Drug: IW-9179
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02289846
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02596126
Drug: Treatment Prevention for Secondary CV
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESC Guideline (2013 guideline on management of stable coronary disease) recommended pharmacological treatment for event prevention.
Study: NCT00087542
Drug: ACP-103
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03160001
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with active RA and receive Etanercept for 8 weeks.: Placebo lactose 500mg cap twice daily
Study: NCT01715610
Drug: Randomization to Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient's post-drainage of antibiotics will receive placebo and not receive antibiotics
Study: NCT01715610
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be randomized to the antibiotic or placebo arm via a random number generator
Study: NCT00425425
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03839771
Drug: AG-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250mg tablets
Study: NCT03839771
Drug: Placebo for AG-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250mg tablets
Study: NCT03839771
Drug: Placebo for AG-221
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg tablets
Study: NCT01886742
Drug: Standard Dose Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: The standard dose of Cefazolin will be administered intravenously.
Study: NCT01886742
Drug: Weight Based Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: The weight-based dose group will receive 30 mg/kg cefazolin dose intravenously.
Study: NCT03573908
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo oral capsule
Study: NCT03386617
Drug: NEPA
Normalized name: cinepazet
DrugBank: Cinepazet (DB13342)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1 of each chemotherapy cycle:~1 tablet of NEPA (NETU 300 mg/ PALO 0.50 mg) 1 hour prior to the start of chemotherapy with dexamethasone 12 mg administered orally 30 minutes prior to chemotherapy Days 2 to 3 Dexamethasone. The time and date of intake will be recorded.
Study: NCT04212364
Drug: Narcan Nasal Product
Normalized name: Narcan Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: All study participants will be trained in how to use nasal Narcan and they will receive a nasal Narcan kit.
Study: NCT00130429
Drug: PYM50028
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01406522
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcrystalline cellulose
Study: NCT00120107
Drug: Black Tea
Normalized name: black tea
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02178644
Drug: Chemo with concomitant Capecitabine and KD018
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive a course of chemo-radiation with concomitant Capecitabine and KD018, and to compare this to the toxicity seen in patients treated with Capecitabine and radiation therapy alone, in patients with T3-T4 and N0-N2, M0 rectal cancer.
Study: NCT03327389
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl was infused at a rate of 0.4 μg/kg/h starting immediately after anesthetic induction and continued until skin closure
Study: NCT00189163
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar Pill, taken orally, once per day, for 48 weeks
Study: NCT02941796
Drug: HCP0918
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02941796
Drug: HCP0816
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03027414
Drug: Transcranial Magnetic Stimulation Sham
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMS device is used to determine the effect of non-invasive brain stimulation on anxiety and anxiety-cognition interactions in healthy subjects.
Study: NCT01782742
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01953003
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arm A : 1650 mg/m² Arm B : 2500 mg/m²
Study: NCT00791323
Drug: Ketorolac 0.4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop 4 times a day in the pre-operative eye beginning day 0 for 4 days
Study: NCT00791323
Drug: Lubricating Eye Drop
Normalized name: Ultra Lubricating Eye Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop 4 times a day in the operative eye beginning one day prior to the peripheral iridotomy and continuing until the day of IOL implantation
Study: NCT01799460
Drug: The Comprehensive Treatment Regimen of Traditional Chinese Medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: ①ShenQiMoShen Decoction: which plays vital therapeutic effect in the CTR,the dosage is 150ml per serving and two services per day.Dosage and administration:150ml per time,twice per day~②HuoXueTongMai Capsule : which plays a vital role of promoting blood circulation and removing blood stasis. Its main components are the leeches. Dosage and administration: 4 capsules 3 times daily.~③HeiLiaoDou Particle: which will be prescribed when hypoproteinemia (serum albumin concentration≤30g/L)occurred and should be stopped taking until the serum albumin is above 30g/L. Dosage and administration: 2 packages 3 times daily.
Study: NCT00668135
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT01166490
Drug: ASG-5ME
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3-3.0 mg/kg IV on Days 1, 8, and 15 of 28-day cycles
Study: NCT00081796
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03644836
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sweet taste cocoa flavored drink
Study: NCT04134065
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: the capsule contain nothing
Study: NCT03685292
Drug: Behavioral Treatment
Normalized name: AspyreRx Digital Behavioral Therapeutic Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study addressed the efficacy of cognitive-behavioral therapy (CBT) treatment.
Study: NCT03906721
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill used to condition patients.
Study: NCT03724266
Drug: Calcium Hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: intracanal medication
Study: NCT00081731
Drug: Atacand/HCT, Caduet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atacand/HCT and caduet or optimal medical therapy for hypertension
Study: NCT00112281
Drug: Tilarginine Acetate Injection intravenous infusion
Normalized name: potassium acetate Injection
DrugBank: Potassium acetate (DB14498)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00861614
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution, Intravenous, 0 mg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase, up to 24 weeks in Induction, 48+ weeks in the Maintenance Phase, or until Treatment Stopping Criteria are met, withdrawal of consent, lost to follow-up, death, study closure
Study: NCT00847795
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01255592
Drug: AZD5069
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose bid
Study: NCT01255592
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose bid
Study: NCT04462523
Drug: Dextenza 0.4Mg Ophthalmic Insert
Normalized name: Dextenza 0.4mg Ophthalmic Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
Study: NCT04462523
Drug: Topical Prednisolone
Normalized name: prednisolone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care topical drop treatment
Study: NCT01404208
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill
Study: NCT00412217
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo tablets (matched to erlotinib) once daily.
Study: NCT00172354
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02691195
Drug: 0.9% Nacl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients were received an ultrasound-guided serratus plane block, the serratus plane was injected with 0.9% Nacl 0.4ml/Kg.
Study: NCT03704584
Drug: Control Group (corticosteroid alone)
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group (corticosteroid alone) subjects will receive (40 mg/mL injection of Methylprednisolone acetate injectable suspension or 40 mg/mL triamcinolone) .
Study: NCT01083641
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg oral three times daily
Study: NCT01685853
Drug: PEG 4 litres split
Normalized name: PEG-4 diheptanoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: * the day before colonoscopy: 2 litres of PEG~* the morning of colonoscopy: 2 litres of PEG starting 5 hours before the examination
Study: NCT00006994
Drug: l-glutamine placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 cc three times daily for 60 days
Study: NCT02607956
Drug: B/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50/200/25 milligrams (mg) FDC tablets administered orally, once daily
Study: NCT02607956
Drug: DTG Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally, once daily
Study: NCT02607956
Drug: F/TAF Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally, once daily
Study: NCT02607956
Drug: B/F/TAF Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally, once daily
Study: NCT01036932
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose of 1ml s/c at days 1, 2, 3, 4, 5, and then every 3rd day till day 28 (total 12 doses) along with the standard therapy.
Study: NCT04048226
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients in this group will be connected to the syringe pump that contain normal saline with starting infusion at a rate of 0.1 ml/kg/hr till the end of the surgery.
Study: NCT01745835
Drug: 2L Coolprep®
Approvals — FDA: no, EMA: no, PMDA: no
Description: \* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g
Study: NCT00636168
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV solution, IV, 10 mg/kg, 4x every 21 days then starting from Week 24 every 12 weeks until Week 156 (3 years), disease recurrence, unacceptable toxicity or patient withdrawal
Study: NCT02691702
Drug: BIIB118
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple ascending doses of BIIB118 (50 mg, 150 mg, 450 mg and 900 mg) as extemporaneously prepared solution/suspension administered once daily over 2 weeks
Study: NCT02691702
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Positive control used to assess the validity of DLMO as pharmacodynamic endpoint.
Study: NCT01634295
Drug: CKD-828 2.5/40mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Fixed dose combination of S-amlodipine 2.5mg and Telmisartan 40mg QD 2 weeks.~* With the others investigation product placebo 4 tabs QD 2 weeks.
Study: NCT01634295
Drug: CKD-828 5/40mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Fixed dose combination of S-amlodipine 5mg and Telmisartan 40mg QD 2 weeks.~* With the others investigation product placebo 4 tabs QD 2 weeks.
Study: NCT01634295
Drug: CKD-828 5/80mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Fixed dose combination of S-amlodipine 5mg and Telmisartan 80mg QD 6 weeks.~* With the others investigation product placebo 4 tabs QD 6 weeks.
Study: NCT03166215
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-935 placebo-matching tablets.
Study: NCT03077659
Drug: NanoPac®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with prostate cancer scheduled for prostatectomy will have NanoPac® injected intratumorally under image guidance directly into the lobe of the prostate with the dominant lesion 4 weeks prior to prostatectomy.
Study: NCT04453800
Drug: sofadil【Neu2000KW】
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 250mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
Study: NCT04453800
Drug: Sofadil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 500mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
Study: NCT04453800
Drug: Sofadil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 500mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
Study: NCT00782600
Drug: suspension IR
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg IR suspension once daily for one day
Study: NCT00782600
Drug: CR 1
Normalized name: Paxil CR 12.5mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg shorter release CR once daily for one day
Study: NCT00985959
Drug: JNJ-26866138 1.0 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-26866138 1.0 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles
Study: NCT00985959
Drug: JNJ-26866138 1.3 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I: JNJ-26866138 1.3 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Phase II: JNJ-26866138 1.3 mg/m2 on Days 1, 8, 22 and 29 of 6-week cycle for 5 to 9 cycles.
Study: NCT00985959
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone 60 mg/m2 will be taken orally (by mouth) on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles
Study: NCT00981851
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 time inhalation of placebo with the amount of puffs similar to the active comparator. cigarette smoking
Study: NCT02553707
Drug: Ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive ibandronate 6 mg IV on Days 1, 2, and 3.
Study: NCT04676685
Drug: E2730-matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2730-matched placebo capsules.
Study: NCT00002756
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002756
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002756
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002756
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002756
Drug: therapeutic hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03803228
Drug: Conventional stimuli
Normalized name: STIMULEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 stimulations by Fertistartkit® performed on 2 different cycles
Study: NCT04907227
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT03221088
Drug: Jintrolong® low dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-somatropin 0.1mg/kg/wk by weekly subcutaneous injection for 52 weeks.
Study: NCT02707952
Drug: ABT-493/ABT-530
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-formulated tablet
Study: NCT02707952
Drug: OBV/PTV/r
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-formulated tablet
Study: NCT00168506
Drug: CBT
Normalized name: Mahana IBS CBT Mobile Application
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00168506
Drug: CBT/SSRI
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02648841
Drug: Adjuvant chemotherapy for experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 cycles of SOX adjuvant chemotherapy will be given to the patients in the experimental group. The SOX chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral, D1-14, Q21D; Oxaliplatin 130mg/m2, ivgtt, D1, Q21d.
Study: NCT00799838
Drug: Ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Formulation: oral solution 20mg/mL~Route of administration: oral~Dose regimen: 1 drop/Kg for children aged between 4 to 6 years old or 25 drops for children from 7 to 11 years old administered t.i.d
Study: NCT00799838
Drug: Placebo (for Ketoprofen)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation: oral solution~Route of administration: oral~Dose regimen: 1 drop/Kg for children aged between 4 to 6 years old or 25 drops for children from 7 to 11 years old administered t.i.d
Study: NCT02006641
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily, matching placebo capsules, orally
Study: NCT04788407
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo TID for 7 days
Study: NCT03579628
Drug: AsiDNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive a loading dose of AsiDNA iv infusion (D1, D2, D3) followed by weekly iv administrations.~At cycle 1: Part B1: Carboplatin will be administered by a 1 hour IV infusion at D8, 1 hour after the end of AsiDNA infusion. Part B2: Carboplatin will be administered by a 1 hour IV infusion at D8, 1 hour after the end of AsiDNA infusion and Paclitaxel will be administered by a 1 hour IV infusion at D8, D15, D22 or 1 hour after the end of AsiDNA infusion for weekly administrations.~At each other cycle: AsiDNA will be administered on a weekly basis. Part B1: Carboplatin will be administered by a 1 hour IV infusion at D1, 1 hour after the end of AsiDNA infusion. Part B2; Carboplatin will be administered by a 1 hour IV infusion at D1, 1 hour after the end of AsiDNA infusion and Paclitaxel will be administered on a weekly basis by a 1 hour IV infusion.~Patients will continue study treatment until disease progression, unacceptable toxicity or patient's refusal to continue.